Sign in
GOSS Stock Price, Chart, Stats & News
Gossamer Bio, Inc.
Save
39.64M
Market cap
–
Current P/E
–
Forward P/E
GOSS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.53% |
Operating margin | -352.23% |
Pretax margin | -351.67% |
Net margin | -351.49% |
Effective tax rate | 0.05% |
ROA | -98.91% |
ROE | 264.70% |
D/E | -1.65x |
Interest coverage ratio | -15.54x |
GOSS valuation
P/E | – |
P/S | 1.68x |
P/B | -0.64x |
P/CF | -0.46x |
P/FCF | -0.47x |
P/OCF | -0.46x |
PEG | 0.05x |
EV multiple | 0.52x |
About
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
Similar securities
Based on sector and market capitalization
Report issue